SCHEMBL12142007

SCHEMBL12142007

CC(C)C1CCN(c2cccnn2)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.45
RIPK1 Q13546 1/20 0.43
GLS O94925 8/20 0.41
SLC6A7 Q99884 1/20 0.41
ACHE P22303 2/20 0.40
DPP4 P27487 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
NPY1R P25929 1/20 0.38
SLC6A2 P23975 1/20 0.38
TACR1 P25103 1/20 0.38
OPRM1 P35372 1/20 0.38
HTR2B P41595 1/20 0.38
SLC6A3 Q01959 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KLF5 Q13887 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26684790 0.91 GLS (0.44) TRPV1RIPK1GLSDPP4DPP8
SCHEMBL14094520 0.81 NPC1 (0.52) TRPV1RIPK1SLC6A7NPY1RNPC1
SCHEMBL25059133 0.81 TRPV1 (0.43) TRPV1RIPK1GLSSLC6A7NPY1R
SCHEMBL12844313 0.81 RIPK1 (0.43) TRPV1RIPK1GLSSLC6A7DPP4
SCHEMBL21917399 0.80 TRPV1 (0.48) TRPV1RIPK1GLSSLC6A7SLC6A2
SCHEMBL2603222 0.79 PLD1 (0.53) ACHEDPP4DPP8DPP9
SCHEMBL2000100 0.78 HTR3E (0.54) TRPV1RIPK1GLSSLC6A7DPP4
SCHEMBL3715603 0.78 RIPK1 (0.48) TRPV1RIPK1GLSSLC6A7DPP4
SCHEMBL21843784 0.78 TRPV1 (0.46) TRPV1RIPK1GLSSLC6A7SLC6A2
SCHEMBL12776572 0.77 TRPV1 (0.45) TRPV1RIPK1GLSSLC6A7DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 US disclosed
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 US disclosed
US-8067589-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2011-11-29 US disclosed
US-8067589-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2011-11-29 US disclosed
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions BLAKE TANISHA D 2009-11-12 US disclosed
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions BLAKE TANISHA D 2009-11-12 US disclosed
US-7582643-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2009-09-01 US disclosed
US-7582643-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2009-09-01 US disclosed
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions BLAKE TANISHA D 2008-08-28 US disclosed
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions BLAKE TANISHA D 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions CYP11B2, CYP11B1, LTC4S TRPV1 254/4885RIPK1 4627/4885GLS 1701/4885
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS HPGDS, PTGS1, PTGIS TRPV1 607/4885RIPK1 3950/4885GLS 94/4885
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions CYP11B2, CYP11B1, LTC4S TRPV1 254/4885RIPK1 4627/4885GLS 1701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.